South Korea Benign Prostatic Hyperplasia Treatment Market Size, Share, Growth, and Industry Analysis, By Treatment Type (Pharmacological treatmentAlpha-blockersTamsulosinSilodosinAlfuzosinDoxazosinOther alpha-blockers5-alpha reductase inhibitors (5-ARI)DutasterideFinasterideCombination therapyAlpha-blockers + 5-arisAlpha-blockers + pde5 inhibitorsPhosphodiesterase-5 inhibitors (pde5 inhibitors)Herbal and other drugs, Surgical treatmentTransurethral resection of the prostate (TURP)Transurethral incision of the prostate (TUIP)Open prostatectomyLaser therapyHolmium laser enucleation of the prostate (HOLEP)Photoselective vaporisation of the prostate (PVP), Minimally invasive proceduresUrolift systemRezūm water vapour therapyProstatic artery embolisationMicrowave thermotherapyTransurethral needle ablation (TUNA), Other treatmentsLifestyle modificationsWatchful waiting / active surveillance), By End Use (Hospitals, Clinics, Ambulatory surgical centres, Specialty urology centers) and Forecast, 2026-2034

Table of Contents

1. Executive Summary
   1. Introduction
2. Market Introduction
   1. Market Definition
   2. Scope of the Study
   3. Market Structure
3. Research Methodology
   1. Primary Research
   2. Research Methodology
   3. Assumptions & Exclusions
   4. Secondary Data Sources
4. Market Factor Analysis
   1. Value Chain Analysis: South Korea Benign Prostatic Hyperplasia Treatment Market
   2. Porters Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitution
      4. Threat of New Entrants
      5. Competitive Rivalry
5. Market Dynamics
   1. Drivers
   2. Restraints
   3. Opportunities
6. Recent Trends Analysis
7. Impact of COVID-19 on South Korea Benign Prostatic Hyperplasia Treatment Market
   1. Pre and Post Covid -19 Market Scenario Analysis
   2. Market Recovery Timeline and Challenge
   3. Measures Taken by Top Players
8. Regulatory Landscape
9. South Korea Benign Prostatic Hyperplasia Treatment Market, By Type
   1. Introduction
      1. Market Size and Forecast, By Type
   2. Drugs
      1. Market Size and Forecast, By Region
   3. Devices
      1. Market Size and Forecast, By Region
   4. Surgery
      1. Market Size and Forecast, By Region
10. South Korea Benign Prostatic Hyperplasia Treatment Market, By Application
    1. Introduction
       1. Market Size and Forecast, By Application
    2. Monotherapy
       1. Market Size and Forecast, By Region
    3. Combination Therapy
       1. Market Size and Forecast, By Region
11. South Korea Benign Prostatic Hyperplasia Treatment Market, By Distribution Channel
    1. Introduction
       1. Market Size and Forecast, By Distribution Channel
    2. Hospital Pharmacies
       1. Market Size and Forecast, By Region
    3. Retail Pharmacies
       1. Market Size and Forecast, By Region
    4. Online Pharmacies
       1. Market Size and Forecast, By Region
12. Regional Overview
    1. Introduction
       1. Market Size and Forecast
    2. South Korea
       1. Market Size and Forecast
          1. By Type
             1. Drugs
             2. Devices
             3. Surgery
          2. By Application
             1. Monotherapy
             2. Combination Therapy
          3. By Distribution Channel
             1. Hospital Pharmacies
             2. Retail Pharmacies
             3. Online Pharmacies
13. Competitive Landscape, 2025
    1. Introduction
    2. South Korea Benign Prostatic Hyperplasia Treatment Market Share Analysis, 2025 (%)
       1. Market Share Analysis, 2025
       2. Competition Ranking, 2025
       3. Key Developments & Growth Strategies
          1. Merger & Acquisition
          2. Product Launch
          3. Expansion
       4. Consolidated SWOT Analysis of Key Players
14. Company Profile
    1. Yuhan Corporation
       1. Business Overview
       2. Financial Data
       3. Key Product domains
       4. Recent Developments
    2. Hanmi Pharmaceutical Co., Ltd.
    3. Daewoong Pharmaceutical Co., Ltd.
    4. Dong-A ST Co., Ltd.
    5. JW Pharmaceutical Corporation
    6. Korea United Pharm Inc.
    7. Boryung Pharmaceutical Co., Ltd.
    8. Bukwang Pharmaceutical Co., Ltd.
    9. Pfizer Inc. (South Korea Operations)
    10. AstraZeneca plc (South Korea Operations)
    11. Bayer AG (South Korea Operations)
    12. Boston Scientific Corporation (South Korea Operations)
    13. Medtronic plc (South Korea Operations)
    14. Olympus Corporation (South Korea Operations)
    15. Karl Storz SE & Co. KG (South Korea Operations